RNXT
RenovoRx, Inc. NASDAQ Listed Aug 26, 2021$0.92
+3.29%
vs $0.89
Mkt Cap $32.5M
52w Low $0.73
27.3% of range
52w High $1.42
50d MA $0.90
200d MA $0.99
P/E (TTM)
-2.9x
EV/EBITDA
—
P/B
6.0x
Debt/Equity
0.0x
ROE
-206.0%
P/FCF
-3.0x
RSI (14)
51.40
ATR (14)
$0.06
Beta
1.22
50d MA
$0.90
200d MA
$0.99
Avg Volume
298.0K
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
4546 El Camino Real · Mountain View, CA 94022 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.08 | -0.08 | +0.0% | 1.07 | +1.9% | -5.6% | -4.0% | +1.0% | -4.9% | -3.4% | — |
| Nov 13, 2025 | AMC | -0.08 | -0.08 | +0.0% | 0.97 | -8.7% | -23.0% | +7.2% | -2.7% | -6.4% | +6.3% | — |
| Aug 14, 2025 | AMC | -0.08 | -0.08 | +0.0% | 1.24 | -19.4% | -22.9% | -1.6% | -2.0% | -5.6% | +2.7% | — |
| May 15, 2025 | AMC | -0.08 | -0.08 | +0.0% | 1.11 | +0.0% | +6.3% | +5.1% | -1.6% | +0.0% | +0.8% | — |
| Mar 31, 2025 | AMC | -0.13 | -0.12 | +7.7% | 0.99 | -1.0% | -3.0% | +4.2% | -9.0% | -3.1% | -10.4% | — |
| Nov 13, 2024 | AMC | -0.12 | -0.10 | +16.7% | 1.09 | +3.7% | +0.0% | +0.0% | -1.8% | +3.7% | +7.2% | — |
| Aug 13, 2024 | AMC | -0.10 | -0.10 | +0.0% | 1.16 | +1.7% | -3.4% | -0.9% | +6.3% | -10.2% | +0.0% | — |
| May 10, 2024 | AMC | -0.14 | -0.07 | +50.0% | 1.45 | -5.5% | -2.8% | +2.8% | -4.1% | +5.0% | -6.2% | — |
| Apr 1, 2024 | AMC | -0.30 | -0.17 | +43.3% | 1.32 | -0.8% | -6.1% | +1.6% | -4.8% | -3.3% | +0.9% | — |
| Nov 13, 2023 | AMC | -0.30 | -0.27 | +10.0% | 1.05 | +6.3% | -28.3% | -1.2% | -15.8% | -4.1% | +1.5% | — |
| Aug 16, 2023 | AMC | -0.25 | -0.22 | +12.0% | 1.71 | +14.0% | +7.6% | -6.5% | +0.0% | +5.2% | -3.3% | — |
| May 15, 2023 | AMC | -0.25 | -0.36 | -44.0% | 2.23 | +0.0% | -0.9% | -5.0% | +2.4% | +0.0% | -5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.94 | $0.92 | -2.0% | +4.2% | +0.7% | +3.5% | +1.0% | -1.0% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.90 | $0.95 | +5.6% | +4.3% | +4.2% | +0.7% | +3.5% | +1.0% |
| Feb 17 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.93 | $0.98 | +4.9% | +5.0% | +2.0% | -5.9% | -2.9% | -1.2% |
| Nov 21 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.78 | $0.79 | +1.7% | +2.2% | -1.3% | +10.2% | +2.4% | +3.5% |
| Aug 25 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.94 | $0.94 | -0.0% | -4.5% | +2.8% | +0.1% | +2.5% | +1.3% |
| Jun 5 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.39 | $1.39 | +0.0% | +0.7% | -0.7% | -1.4% | -2.2% | +1.5% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.18 | $1.24 | +5.1% | +5.1% | -1.6% | +0.0% | +0.8% | -3.3% |
| Apr 28 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.99 | $0.98 | -1.0% | -1.8% | -0.2% | -1.0% | +3.1% | +1.0% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.91 | $0.92 | +1.2% | -3.1% | -10.4% | +1.3% | +3.8% | -4.7% |
| Dec 10 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.43 | $1.41 | -1.4% | -4.2% | +2.9% | -6.4% | -3.0% | -2.3% |
| Sep 12 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.05 | $1.10 | +4.8% | +1.9% | +5.6% | -6.2% | -4.7% | -2.0% |
| Nov 15 | Maxim Group | Downgrade | Buy → Hold | — | $0.75 | $0.78 | +3.0% | -1.2% | -15.8% | -4.1% | +1.5% | +2.0% |
| Aug 18 | Roth MKM | Maintains | Buy → Buy | — | $1.84 | $1.91 | +3.8% | -6.5% | +0.0% | +5.2% | -3.3% | -1.7% |
| Nov 1 | Roth Capital | Maintains | Buy → Buy | — | $5.18 | $5.39 | +4.1% | +5.4% | +0.2% | -0.7% | +0.2% | -3.3% |
| Oct 6 | Maxim Group | Maintains | Buy → Buy | — | $5.72 | $5.80 | +1.4% | +3.3% | +4.1% | -7.2% | -3.7% | +2.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 | VOLL MARKOff | Chief Financial Officer | Buy | 25,000 | $0.79 | $20K | 142,380 | -0.01% | -8.05% |
8-K · 2.02
!! High
RenovoRx, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
RenovoRx's modest $1.1M first-year revenue and $13M cash position suggest extended cash burn ahead, making dilution likely before Phase III trial completion in 2027, warranting caution on near-term shareholder returns.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
RNXT's CEO departure effective February 27, 2026 creates leadership uncertainty that could pressure the stock until a successor is named and their strategic vision is clarified.
Mar 27
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
RNXT's equity issuance will dilute existing shareholders' ownership stakes and may pressure stock price unless proceeds fund high-return growth initiatives.
Mar 23
8-K · 5.02
!!! Very High
RenovoRx, Inc. -- 8-K 5.02: Executive Change
RenovoRx appointed Mark Voll as CFO while he simultaneously resigned as a director, signaling a potential leadership restructuring that investors should monitor for strategic implications.
Feb 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Aigh Capital Management Llc | 3,706,197 | $4M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,447,177 | $1M | New | Mar 2026 |
| 3 | Wealthspire Advisors, Llc | 252,525 | $255K | — | Mar 2026 |
| 4 | Citadel Advisors Llc | 232,684 | $235K | Added | Mar 2026 |
| 5 | Corsair Capital Management, L.p. | 93,473 | $119K | Reduced | Sep 2025 |
| 6 | Caprock Group, Llc | 63,940 | $65K | — | Mar 2026 |
| 7 | Northwestern Mutual Wealth Management Co | 74,616 | $63K | — | Dec 2025 |
| 8 | Hrt Financial Lp | 43,120 | $43K | Added | Mar 2026 |
| 9 | Northern Trust Corp | 42,161 | $43K | — | Mar 2026 |
| 10 | Cypress Point Wealth Management, Llc | 20,000 | $20K | — | Mar 2026 |
| 11 | Hightower Advisors, Llc | 20,000 | $17K | Reduced | Dec 2025 |
| 12 | Affinity Capital Advisors, Llc | 13,279 | $13K | — | Mar 2026 |
| 13 | Renaissance Technologies Llc | 13,000 | $13K | Reduced | Mar 2026 |
| 14 | Captrust Financial Advisors | 12,307 | $12K | — | Mar 2026 |
| 15 | Jane Street Group, Llc | 13,905 | $12K | Added | Dec 2025 |
| 16 | Ground Swell Capital, Llc | 13,611 | $11K | New | Dec 2025 |
| 17 | Focus Partners Wealth | 11,000 | $11K | — | Mar 2026 |
| 18 | Ubs Group Ag | 3,338 | $3K | Added | Mar 2026 |
| 19 | Morgan Stanley | 2,242 | $2K | New | Dec 2025 |
| 20 | Citigroup Inc | 1 | $1 | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 179,825 | $159K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 77,982 | $69K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 49,555 | $44K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 7,791 | $7K | Feb 2026 |
Valuation
Market Cap
$32.5M
Enterprise Value
$25.6M
P/E (TTM)
-2.88x
Forward P/E
—
PEG Ratio
0.20x
P/B
5.99x
P/S
28.95x
P/FCF
-2.96x
EV/EBITDA
—
Shares Out
35.3M
Financials (TTM)
Revenue
$1.1M
Net Income
-$11.2M
EBITDA
-$12.5M
Free Cash Flow
-$11.0M
Op Cash Flow
-$11.0M
EPS Basic
$-0.32
EPS Diluted
$-0.32
EPS Forward
$-0.28
Gross Margin
70.9%
Op Margin
-1114.0%
Net Margin
-994.5%
Balance Sheet
Total Assets
$8.1M
Total Liab.
$2.7M
Total Equity
$5.4M
Cash
$7.0M
LT Debt
$107K
Book Value/Sh
$0.15
Debt/Equity
0.02x
Current Ratio
4.02
Quick Ratio
3.93
Returns & Growth
ROE
-206.0%
ROA
-138.0%
ROIC
-204.0%
Rev Growth YoY
+2511.6%
EPS Growth YoY
+13.5%
Price Returns
2W
+6.4%
1M
+7.0%
3M
+3.0%
6M
-0.9%
12M
-35.0%
Technicals
52W High
$1.42
52W Low
$0.73
50d MA
$0.90
200d MA
$0.99
RSI (14)
51.40
ATR (14)
$0.06
Beta
1.22
Avg Volume
298K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 11:17pm
· Source: financialmodelingprep.com